Sign in

Private company

Berna Biotech

Logo: Schweizerische Serum- und Impfinstitut Bern Berna Biotech AG, Bern-Bümpliz, Public domain, via Wikimedia Commons3

Swiss vaccine manufacturer

Berna Biotech AG, historically the Schweizerisches Serum- und Impfinstitut Bern (French: Institut sérothérapique et vaccinal suisse Berne; English: Swiss Serum and Vaccine Institute Bern), known as Berna, was a Swiss vaccine manufacturer based in Bern. Its activities centered on the development, production, and distribution of immunobiological preparations—bacterial and viral vaccines and plasma derivatives—as well as pharmaceutical and veterinary products.2 It is part of Janssen Vaccines.1 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

1898Founded1

See how the biggest companies compare on our leaderboards

Berna Biotech AG, historically the Schweizerisches Serum- und Impfinstitut Bern (French: Institut sérothérapique et vaccinal suisse Berne; English: Swiss Serum and Vaccine Institute Bern), known as Berna, was a Swiss vaccine manufacturer based in Bern. Its activities centered on the development, production, and distribution of immunobiological preparations—bacterial and viral vaccines and plasma derivatives—as well as pharmaceutical and veterinary products.2

Corporate structure

Berna Biotech is part of a group headed by Janssen Vaccines. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

The company was formed in 1898 from the merger of the Institut Vaccinal Suisse at Lancy (founded in 1883) and the firm Häfliger, Vogt & Cie in Bern (founded in 1895). Under its founders Charles Haccius, Johann Friedrich Häfliger, and Albert Vogt, the new institute quickly made a name for itself by producing a smallpox vaccine, followed by vaccines against epidemic diseases—including diphtheria, cholera, poliomyelitis, typhus, meningitis, hepatitis, and influenza—as well as products for emergency medicine and veterinary care.

The intranasal influenza vaccine Nasalflu produced by Berna Biotech and used during the years 2000 and 2001 was found to have a strong association with cases of Bell's palsy. The vaccine had been withdrawn in 2002 due to concerns about a link to the disease.

Through intensive research, including in the most recent technologies such as genetic engineering, and continual development of its products, the institute gained access to world markets, particularly through subsidiaries in Europe, Argentina, and Korea, and through international organizations such as UNICEF and the WHO. The company was renamed Berna Biotech AG in 2001 and had 850 employees worldwide in 2004, including 400 in Switzerland. In 2006 it was taken over by the Dutch firm Crucell, and in 2011 Crucell Switzerland AG was acquired by the American group Johnson & Johnson.

From Wikipedia’s article on Berna Biotech, shared under CC BY-SA 4.0.4

Products and brands

  • vaccine

Listed on Wikidata.1

Subsidiaries and ownership

Parent company

Owners

From Wikidata.1

Timeline

  1. 1898Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4